MedTrace Logo

Phase I Clinical Trial of a Candidate HPV Vaccine

NCT05672966 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-01-06

No results posted yet for this study

Summary

This is a Phase I, first-in-human, randomized, observer-blinded, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of BV601 (a HPV Vaccine) in healthy adult volunteers.

Conditions

  • Human Papillomavirus Infection

Interventions

BIOLOGICAL

Human papillomavirus (HPV) Vaccine

0.5mL, Intramuscular

BIOLOGICAL

Placebo

0.5mL, Intramuscular

Sponsors & Collaborators

  • Shanghai BravoBio Co., Ltd.

    collaborator UNKNOWN

  • Novotech (Australia) Pty Limited

    collaborator INDUSTRY

  • Wuhan BravoVax Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-07-31
Completion
2024-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05672966 on ClinicalTrials.gov